0001564590-21-050957.txt : 20211015 0001564590-21-050957.hdr.sgml : 20211015 20211015164500 ACCESSION NUMBER: 0001564590-21-050957 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20211015 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20211015 DATE AS OF CHANGE: 20211015 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CRYO CELL INTERNATIONAL INC CENTRAL INDEX KEY: 0000862692 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MISC HEALTH & ALLIED SERVICES, NEC [8090] IRS NUMBER: 223023093 STATE OF INCORPORATION: DE FISCAL YEAR END: 1130 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40767 FILM NUMBER: 211326470 BUSINESS ADDRESS: STREET 1: 700 BROOKER CREEK BLVD STREET 2: SUITE 1800 CITY: OLDSMAR STATE: FL ZIP: 34677 BUSINESS PHONE: 813-749-2104 MAIL ADDRESS: STREET 1: 700 BROOKER CREEK BLVD STREET 2: SUITE 1800 CITY: OLDSMAR STATE: FL ZIP: 34677 8-K 1 ccel-8k_20211015.htm 8-K ccel-8k_20211015.htm
false 0000862692 NONE 0000862692 2021-10-15 2021-10-15

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 15, 2021

 

CRYO-CELL INTERNATIONAL, INC.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-40767

22-3023093

(State or Other Jurisdiction

of Incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

 

 

 

700 Brooker Creek Blvd., Suite 1800, Oldsmar, FL

 

34677

(Address of Principal Executive Offices)

 

(Zip Code)

Registrant’s Telephone Number, Including Area Code: (813) 749-2100

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange on which registered

Common Stock, Par Value $0.01

 

CCEL

 

OTCQB

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

Item 2.02.

Results of Operations and Financial Condition.

On October 15, 2021, Cryo-Cell International, Inc. (the "Registrant") issued the attached Press Release reporting on financial results for the three months ended August 31, 2021.  The press release giving details associated with the Registrant's earnings is attached as Exhibit 99.1 to this report.  The information included in Exhibit 99.1 is considered to be "furnished" under the Securities Exchange Act of 1934.

 

Item 9.01. Financial Statements and Exhibits.

 

Financial Statements of Businesses Acquired

Not Applicable

 

Pro Forma Financial Information

Not Applicable

 

Shell Company Transactions

Not Applicable

 

Exhibits

 

 

Exhibit No.

Description

 

99.1

Press Release, dated October 15, 2021

 

104

Cover Page Interactive Data File – the cover page iXBRL tags are embedded within the Inline XBRL document

 

 


 

 

 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

 

 

 

 

 

 

 

 

 

 

CRYO-CELL INTERNATIONAL, INC.

 

 

 

 

Dated: October 15, 2021

 

 

 

By:

 

/s/ David Portnoy

 

 

 

 

 

 

David Portnoy

 

 

 

 

 

 

Chairman and Co-Chief Executive Officer

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 EX-99.1 2 ccel-ex991_6.htm EX-99.1 ccel-ex991_6.htm

Exhibit 99.1

 

For Immediate Release

Contact:

 

 

 

 

 

Irene Smith

 

813-749-2102

 

Ismith@cryo-cell.com

 

 

CORD BLOOD BANKING LEADER CRYO-CELL REPORTS FISCAL THIRD Quarter 2021 FINANCIAL RESULTS

 

OLDSMAR, FL – October 15, 2021 – Cryo-Cell International, Inc. (The Nasdaq Stock Market Symbol: CCEL) (the “Company”), the world’s first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal third quarter ended August 31, 2021.

  

Financial Results

 

Revenue

Consolidated revenues for the third quarter of fiscal 2021 were $7.5 million compared to $8.1 million for the third quarter of fiscal 2020.  The revenues for the third quarter of fiscal 2021 consisted of $7.3 million in processing and storage fees, $18,200 in product revenue and $158,936 in public banking revenue compared $7.5 million in processing and storage fees, $427,874 in licensee income, $82,800 in product revenue and $116,826 in public banking revenue for the third quarter of fiscal 2020.  

 

Net Income

The Company reported net income for the three months ended August 31, 2021 of $857,000, or $0.10 per basic share and diluted share, compared to net income of $784,000, or $0.10 per basic and diluted share for the three months ended August 31, 2020. During the three months ended August 31, 2021, revenue decreased 8%, cost of sales increased 4% and selling, general and administration expenses increased 3%.  Selling, general and administrative expenses increase was mainly attributable to $167,000 in expenses associated with the development of the Cryo-Cell Institute for Cellular Therapies’ and $131,000 in patent expenses related to the Patent and Technology License Agreement with Duke University (“the Agreement”). Also, for the three months ended August 31, 2021, the Company recorded $255,000 in amortization expense related to the Agreement.  For the three months ended August 31, 2021, the Company recorded a decrease of $325,000 versus $146,000 for the three months ended August 31, 2020, to the fair value of the contingent consideration liability from the potential earn out to which Cord:Use is entitled from the Company’s sale of the purchased public cord blood inventory

 

David Portnoy, Chairman of the Board and Co-CEO, commented, “We are proud to report another quarter of solid financial results even with the additional expenses related to our transformation into a vertically integrated, cellular therapy company.”

 

About Cryo-Cell International, Inc.

 

Founded in 1989, Cryo-Cell International, Inc. is the world’s first private cord blood bank. ‎More than 500,000 parents from 87 countries have entrusted Cryo-Cell International with ‎their baby’s cord blood and cord tissue stem cells. In addition to its private bank, Cryo-Cell ‎International has a public banking program in partnership with Duke University. Cryo-Cell’s ‎public bank has provided cord blood for more than 600 transplantations and operates cord ‎blood donation sites across the U.S in prominent hospitals such as Cedars–Sinai Hospital in ‎Los Angeles and Baptist Hospital in Miami. Cryo-Cell’s facility is FDA registered,

 

cGMP-/cGTP-‎compliant and licensed in all states requiring licensure. Besides being AABB accredited as a ‎cord blood facility, Cryo-Cell was also the first U.S. (for private use only) cord blood bank to ‎receive FACT accreditation for adhering to the most stringent cord blood quality standards ‎set by any internationally recognized, independent accrediting organization. Cryo-Cell owns ‎the exclusive rights ‎to PrepaCyte-CB, the industry’s most advanced cord blood processing ‎technology.‎

 

Cryo-Cell’s mission is to provide the premier cord blood and cord tissue cryopreservation services and to develop, manufacture and administer cellular therapies to significantly improve the lives of patients worldwide.  In February 2021, Cryo-Cell entered into a license agreement with Duke University ‎that transformed Cryo-Cell into an autonomous, ‎‎vertically ‎integrated cellular therapy ‎company. ‎

 

For more information, please visit IR.cryo-cell.com.

 

 

Forward-Looking Statements

 

Statements herein the terms “believe”, “intends”, “projects”, “anticipates”, “expects”, and similar expressions as used are intended to reflect “forward-looking statements” of the Company. The information contained herein is subject to various risks, uncertainties and other factors that could cause actual results to differ materially from the results anticipated in such forward-looking statements or paragraphs, many of which are outside the control of the Company. These uncertainties and other factors include the impact of the COVID-19 pandemic on our sales, operations and supply chain, the success of the Company’s global expansion initiatives and product diversification, the Company’s actual future ownership stake in future therapies emerging from its collaborative research partnerships, the success related to its IP portfolio, the Company’s future competitive position in stem cell innovation, future success of its core business and the competitive impact of public cord blood banking on the Company’s business, the success of the Company’s initiative to expand its core business units to include biopharmaceutical manufacturing and operating clinics, the uncertainty of profitability from its biopharmaceutical manufacturing and operating clinics, the Company’s ability to minimize future costs to the Company related to R&D initiatives and collaborations and the success of such initiatives and collaborations, the success and enforceability of the Company’s umbilical cord blood and cord tissue license agreements, together with the associated intellectual property and their ability to provide the Company with royalty fees, and those risks and uncertainties contained in risk factors described in documents the Company files from time to time with the Securities and Exchange Commission, including the most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and any Current Reports on Form 8-K filed by the Company. The Company disclaims any obligations to subsequently revise any forward-looking statements to reflect events or circumstances after the date of such statements.

 

 

 

 EX-101.SCH 3 ccel-20211015.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000 - Document - Template Link link:presentationLink link:calculationLink link:definitionLink 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 ccel-20211015_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity Central Index Key Cover [Abstract] Document Type Document Type Amendment Flag Amendment Flag Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Incorporation, State or Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address Address Line1 Entity Address, Address Line Two Entity Address Address Line2 Entity Address, City or Town Entity Address City Or Town Entity Address, State or Province Entity Address State Or Province Entity Address, Postal Zip Code Entity Address Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre-commencement Tender Offer Pre Commencement Tender Offer Pre-commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Title of 12(b) Security Security12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 5 ccel-20211015_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 6 ccel-8k_20211015_htm.xml IDEA: XBRL DOCUMENT 0000862692 2021-10-15 2021-10-15 false 0000862692 NONE 8-K 2021-10-15 CRYO-CELL INTERNATIONAL, INC DE 001-40767 22-3023093 700 Brooker Creek Blvd Suite 1800 Oldsmar FL 34677 813 749-2100 false false false false Common Stock, Par Value $0.01 CCEL false XML 7 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Document and Entity Information
Oct. 15, 2021
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Oct. 15, 2021
Entity Registrant Name CRYO-CELL INTERNATIONAL, INC
Entity Central Index Key 0000862692
Entity Incorporation, State or Country Code DE
Entity File Number 001-40767
Entity Tax Identification Number 22-3023093
Entity Address, Address Line One 700 Brooker Creek Blvd
Entity Address, Address Line Two Suite 1800
Entity Address, City or Town Oldsmar
Entity Address, State or Province FL
Entity Address, Postal Zip Code 34677
City Area Code 813
Local Phone Number 749-2100
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, Par Value $0.01
Trading Symbol CCEL
Security Exchange Name NONE
Entity Emerging Growth Company false
EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 1 96 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.cryo-cell.com/20211015/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports ccel-8k_20211015.htm ccel-20211015.xsd ccel-20211015_lab.xml ccel-20211015_pre.xml ccel-ex991_6.htm http://xbrl.sec.gov/dei/2021 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "ccel-8k_20211015.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "ccel-8k_20211015.htm" ] }, "labelLink": { "local": [ "ccel-20211015_lab.xml" ] }, "presentationLink": { "local": [ "ccel-20211015_pre.xml" ] }, "schema": { "local": [ "ccel-20211015.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/currency/2021/currency-2021.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "https://xbrl.sec.gov/exch/2021/exch-2021.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/naics/2021/naics-2021.xsd", "https://xbrl.sec.gov/sic/2021/sic-2021.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 3, "total": 3 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "ccel", "nsuri": "http://www.cryo-cell.com/20211015", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "ccel-8k_20211015.htm", "contextRef": "C_0000862692_20211015_20211015", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.cryo-cell.com/20211015/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "ccel-8k_20211015.htm", "contextRef": "C_0000862692_20211015_20211015", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cryo-cell.com/20211015/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cryo-cell.com/20211015/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cryo-cell.com/20211015/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cryo-cell.com/20211015/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line1", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cryo-cell.com/20211015/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address Address Line2", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cryo-cell.com/20211015/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cryo-cell.com/20211015/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cryo-cell.com/20211015/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cryo-cell.com/20211015/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cryo-cell.com/20211015/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cryo-cell.com/20211015/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cryo-cell.com/20211015/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cryo-cell.com/20211015/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cryo-cell.com/20211015/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cryo-cell.com/20211015/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cryo-cell.com/20211015/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cryo-cell.com/20211015/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cryo-cell.com/20211015/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security12b Title", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cryo-cell.com/20211015/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cryo-cell.com/20211015/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cryo-cell.com/20211015/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cryo-cell.com/20211015/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cryo-cell.com/20211015/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 15 0001564590-21-050957-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001564590-21-050957-xbrl.zip M4$L#!!0 ( )V%3U,Q#0HOM 0 &86 1 8V-E;"TR,#(Q,3 Q-2YX M[XS&7[U=+AIY 2)KRJU[DAST$G*0)Y8NK7BX] M+ FEO??7O_YR^9OGH?'MW2=T0Q1]@C&5A*4R%_#F_N-;]/7/Z03=DT=88C1. M2;X$KI"''I7*1D'P_/SL)W/*94_R7 &P(:(P5(/L;H3B, M(R\*O6CP$)V/!N$H[OMA/QR>Q1A7&#]C M\ATO -V-*XRS<-X?#,-A%,'Y6=P?X&@X.X\3;0G^.#^;S:M(TVPMZ.)1H3?D MK86H_>4<&(,UNJ4< HEMT+ M(Z]?"DF5B6;UAE+3+X4Z9* D-5B %7ELMF H=0N4',!"28W1$!-5YS4XXC < M! 6Q@KH1;Q-2GB_C)J5QJ+$JX)+.&'BQ-4.G%IDC*^"\PSAK#;P@-%CFF M1#:[;$E[3F]3P111U>]^H M*Z7P#QT_2G"NQ;E:_(=8,,,J_']%OR#,L2_VK M/?[GON6.+BXN DLMH>1"Z$YR",N&6@-#"+":T6AC4*HX%C3Y38 M2'+#?W MD--LRGVCQUO&"2!^U'-.1W:P[MV'9SZ.0FKN&ETA5,N]_&H!HMXN.J)PMZ=9 MG&Y[>^=VS(R&1F2_Y4D5T=C&.@:@O'WMZO005&[M;A7)A BP(")EH.](HCZL M,H8Y5JG-Q/#"=(AH>&J'N*CI\F"K[%9_OP2C5 J)5 M+SLPB!3+TS.E.L)T-.X&/[,XW?!V7&QI=F] #( I:Z+858O\V#YMNH:B.M,7X=CLM E&T\/@50&U MSA.C&\/6AFB>OI^@*6^ M*Q1,[$/%D+Y,[TX8X8N66I=N]X J43E<"D-RS%)@AG)60?!+;+#:*/_[8##*19B 4U;E2>:M:!8\"YE<]\Z;TW#%^8WCFZW-S+'L&ZH=G#UV+ M )MLX3E91941GABR/27Y#F%6JC;Y>]63NGA8^8[YW]W5J=#6W=WL:?;Z&ULS5Q; M4^,V&'WO3/^#FGU9INOXP@(EL[!# W0R98$AV7:GGWX,(+T!.\1,S#A"TI?#_\ M<@"^_?YP VZ0_V/L,@@NB;><0S\ !G@,@D7/-)^?G[N3*?(9P"OYU\'$_3E9+%FJ+98P#>>P=AB?QX?1]B#-?@&OFN[R$7@V%RI!_ MP/>ZX )C\""F,? &:1/<-*-43'7K8<3\;A'/@O_/.NDU%N-*>X2.C,=RSHT MD]&=>/AJ:_SS83C:/CT]-#\P-%]@ MKHK9N-1;&*BM=A-0=<'WD"(RN?(5BRR';:?X8>!2Q:KG :L^@!$_OT&UI6]# M*B^:!"Y67/06I,*B:V0CV*ZS:1"F+AN'-/R2/'/=142%!:CIKA"[A%-WB8/M M,AF?'-:XA2 N4R;$ 1-[!!PSPHNK9<>GWG<2X/S*PUK$Y3X>*1 +K@I1_=$U M*(4,5P'T)S ^[;]@$R__P!CTNC/R9$X@BHZ);X1'$AX#_^/[E1^@8-WGJP_J MX@&'7_T)UUE>+*YCA"8[PX,YZQ1,-K,%BO'B8LJWQ,()^L;785FP[WB\D0P* M&5G2\$I;6LO@M7//(QH0\X"0"'"F3^9K0=OU7U O4X5+O:0 OKFCAGB$Z1&^ M0E@$!D[G?4K)O%#-F);L5,E4F8L^X0O?BS'C-%Y0-@\;D^KE( .BQO](\/,0 M&?R;8/^W?\OE*I-<(91:G-QVC/CAE74X.Z>>P6D,]?W]$ M+H+B2EHVB^$%9Y@(EFOLSLKF<&-2/=TR(.J3^ (/!/[^HR@7FN1JH8VHN)J> M:LZ*+_=9X@E+U=/CQN1F;9T!:_&$&?$ 3A0^5=I_8(NM(#M5TD[VS=-J:<55 MK/$?X R)M80?W+KSTHF6SVVRPL]BM;; ?Z4!@F?_:2YT@>Q22#?%<7VQ]WLO MF"V\PFV@BAX<^!ZA"T+#Y\+#@/=\GRQY!>L^F51LR1U03?)2"-U:PV98/X"0 M%Q *8FX@R'7IXG(^DHJB:NX9SK+N4WD?L5I MK1\$!8@X=(F]1'52I(I."N/JXJH(ZLA=#2;\(H.F*'HUL$YJ M.1_($FJ6[EU6D=+J:6L+;NJ(BI:XF$QX[2S^=8-\:%=K!RE $\TE@*VU04SR M(=D0;P.!X,[79FU39 \II9J65F"9"QD3[+>.O=,T]HYJK9TWCOWHF>@;>Z=L M[)TV8J_(BMVQ=]XD]GV^>4='Y-FO%?KT= 4ZO\*U'WC!)>YC!9MF89>8(HOZ MIEH:&B"/>2C]W2[I%:8\O V^H_>4/"'?J_A$)P]#@=P;F.V'_N7I34*I6?+S MC)+%7RJ>KJ;(&R&RXZZ,'0J[X9ZPP,7_H$7UIYMR! 6B9Q#;[X.(#G ^K9Y? M%AHDZP&);'J:(<]_:1L:OFE*'!J%;I6\9^?4?,M4"D-]IL.KJ(#7),)2E4F> M$KHHBJN)V2R(XJ,'^/Z1^!4?DF_/JR??)H[Z4(8,(*30YC%BKNJD2!6=%,;5 MQ6T6U+\I"@+H]\E\OO3CAY"L;%IS)M<35 JF/KS. \)1AX*D#_[PA?<%+FX;)9E,^MINHVD/L6O'" AV7^$"\0GQ=+H)32N MH7&SV-Y3*/H#NOF(ZN/,N0PO108B-A#2[3_8 M)>PAY433TPK\X@+H5W=!:?0'C"TA;=X $APEVF_AOD$S1)QZ]T2^;_+.R-%1 M9X_RNJ22/0V7-]!;\O74VG;&(Q3@TL\XMN?5O.)NX*@/?P@+R!38SOOQ 4@( M]Y_W7.E)D30ZR9PL:U[!08C>5EA'U!7?U#%D]#)\8U(]_3(@+60T@@<1 M_OZC*1>:Y&JAC:BXFIYJSIU7*^^1'RBL\B$,^=QFS9W&:N$&,68!"8TF'\(H M=('L4D@WQ7$]L56\Q'\-R(%H\KJ2%+*U5_D2 M-A#1@9AO_RDO8Q$IJ9NF=N!:3J1WW/ M\752\2X4?<72^?]02P,$% @ MG85/4[*AHI0$!0 &BT !4 !C8V5L+3(P,C$Q,#$U7W!R92YX;6SE6EN/ MXC84?J_4_^"F+[MJ@[1;&Y M@.YQ3%'RJJ/ "WS;]VR_VO=K]:I7#RJ.5_&NKX+K7SRO[GE; ?Y>=0MMO>JH MZGB.[]2\8,NP@\E7/**H=;]E./"&E>JU=^W[M'855*K8OQ[4@A!:HK_5K@;# M;:1RLE1L-([1._(^@0C]%8)R3I?H@0DL",,<]=*>_HI:@CBHR3GJ&C>-NE13 M-:.ALX[*@;=5W-3:6ILO]NSGE<3:O[FY M<9.K&U/-\@PAK.]^?FSWR)A&V(:A@BP@I@'-ZCKYLRU),D8GX$('+))%9@A\SZ^ZQM3M MTVC"(8?:JRXGL<:*#AL6 0\[-3;-_9QG&R\GD/::P17HO/LV1#%>2"&CY0I: M>ENDGTT1?A(QBY!+F(J0AJF M84P'"NIQ BD%Q2798<"TJ*'))(DT)U%X?87-S-!;1@/)3\7UPJD0OOQ@T&A-J>AS/"\*[1]( M+%!*P\-4L-7\J$]%=\#YH@#-I,T[8RCFGJ;1X/3!W?>[**P[N!^;4//=R?#D M^WC7YZ)P5J+?#$.8$W5'0NW#_V63<\"]%J$XJ#V8ONFSZB@Y8ZMJ[7RP>S&* M@VM&\%GUY5Q\$])M]^) KC^@)*+!-\'<#?!=@/IO!>H7 K2/%ZT0I@8V7*O; M>1IT)$@!@!\8/U,G]_T*@ 4K2*DF4B7=3^[7.SD5L5J>KU!'0A4 _@[&3F'> M@NI@\2<]LP[?.F(961'Q.!9[O>U%XZ;*I Y6+A)53:#9'3L5WP/FB M )O00&@:>>!X="JP%TZ%,-8'#.<2M?*Y;)4C9U0U!R9!2'QRF;/KM MH>]'> M5&0G)%8D#0=?]U;LN_LP:PMW@A7$L\F8\KF/>/,2"FIUK[V;#HC MIZ1:>_RD04912?5W_\Q(1DE)]??%T9X-'U=EU=W<(U@9+255WE?/SV7L? ?I MO77WR($U[%=SY'9UQ;R98Z@?_@-02P,$% @ G85/4QK:00%.$0 ^JD M !0 !C8V5L+3AK7S(P,C$Q,#$U+FAT;>T]:W?J.)*?=\_9_Z"EMV>3L[&Q M#8% 'G-R"?<.V_>2;*!G>O=+'V$+T,;8'LDD87[]5,DV&' 22 B0M//A7FR] M2J5ZJ:HDG_WY<>02RSU&?OMR^YU<^?9XQ+R0:&08AD&] M6'QX>-"=/O>D[XY#&$?JMC\J$DU+.FX(1K& 7-&0$?57)Y9AF9II:.9QUZS6 MCXVZ5=*-DE$I6Y7_,HRZ8:0Z^< 9+ZJY-CW=!-O6I8J8HWU+ZC T9:5ZF* M/:-?.JX8%=-DU;)5.J9FI5>U'!B)G53+O7X:4C^8"#X8AN3 /E0@PGP]C[DN MFY"OW*.>S:E+.LE,CP UMDXN79?<8C-);IEDXIXY>MSK,(05@%7P9/VQ)UQ^ M7DAA#=_HOA@4+<,H%0&#(0S "JGZSJQ!NG*E&!4F56V;N7,]VV+B:_#256N! M$S$-\SBI/I9:. F8G#;I4]E3?2RQ$,#?D^S:2>E\$W_LA>*I M%E'A_(R]\F*I!E-S-8>"AI#HP:[5: M495.*2X43[)+K0BE2<6E+N<9"XM[5$X9BTN_;)G5YU@QJC&%6?(LB*&J6?SM MQ_>./60CJBWR+W]\:@03F1U%*DK4*=F!H!F/7J -J*0IQ')[VN[E1O,-^&.8 MW6 &4S$4U)-]7XS4 B+(QYIA:58EU8D&5#+744(U+_5S,N/*IPD!!6=!25!& M'?Q_Q$*J5([&_C[F]^>%AN\!M85:%^98(';T=%X(@0B+JC4I8KN0ARZ#'R@C MM9.[WQ-AJ$,=*"XFY6?%9"34!.UOH P\T)PA$^0>=8VE'R<[DXLSA]\3 M&4Y<=EYPN Q<.L$U9 CTOYSQQSIVQP0^18_<<9BG'M4SU&U'"T.X53^I6)6:-9W2]$?AHD]=R:0T&$@MP"4)LA3Z@U8 M&TK6@Z-]W6YF0:#>I98% 1*LSU!(,AD#B<*C+A6'PV!$":@ZLM5Y0?)1X"*[ MJW=#@; H*IN2V*-TDF(J;.$CK:PLIM:0E*L*P(NSXOQ\9GA8F'B$"^F/Q0P5 MRH"IQYA7Z_42YE6[I"%3%!6_2UYR!U_W.7"9 HIE2I1&ZY=Y=A>%!8HL0S=*+F3V:=#(KFV\#//E$BZ1D'ICTP,F[&(EI]*=P'1%F M(C[.BB!I\/\@$3.H4% '=Q-J!)S!LDV85,]4I&)KP]9[O.NF13Z#Z MRT B)"!?0-&Y4>=3S:>40E3KG@I.84025RQ<_-IN=9M7I-.][#8[GVA>G6;C MU]M6M]7LD,OV%6G^UOC+9?M;DS2N?_QH=3JMZ_9V)VN]YV3_=MGY2ZO]K7O= M/B)7>D.'C>-QN496GB'.IP8 HM6D#:,)E.$YYKD8 ;#IY XQ4RP7%SS+=2[K M0V> G?A91+W#BRSL*6155L%5C.<8!V]"WYI,G6!K>X(]AW8'6(V@[=.AD L QKW!Q;8=^C^':'2GW:B[!MB/!7F]$V;[K MB_I/D>9*3=@JOR?7/TVQI64GQ2T;<(G]ANO[!AJW_WNM-9K?OY-6N]N\;5]V MP3:]_'X$CXU%XM2W:K-6]>/WQ# Y:#Y2$)"(S$B:)$@D5)).P&S<6#N$>Z05 M2M(84G2%'>8,^B8&?15]*/AKNX0_=D"$%#?^T0*>%\".Q0B3#*BMPHGQ<[R. MZGENUG4Z#OUD^4&LN#20K)[\."4/W F'H!]AVLKQ&RKG1^B0>T5>Z(- K$U[ MC>J72GJI'+=X"V.F*0N?YU<"7^Q,X3\M#(^7A6'+LWT!FE\YW#LAZ.!&%,1I M^,[KE3GZ^M$A%K) ^/:L&#I[OGX9JFVGJUE97LVO MW&50$TRF=5WOIE8VJI5JOC0;69KJ\M)TZ6,K]C_;BME>LTZ6I94,JV342L\M M5#$6A1]"(&[#>#E0@@TW@=>P^1/DOV'O)QVN=H<;,-+V>>I@JLV)^,,/PM'; MHXV&/QIQJ1*&4'R2B"]S/"WBJ77;(Q.=YV"_$NR/HJ;WS;@Z63:N+AU',"GC_[YSCYGK&595 MPR!?A._?@770$(S=D2_NO;/DT3EZQC=:6P4L:SVP.F,.=HMY8AB+H#P#B6D\ M"4D#?EZ+KO_@K0?'M>M(H)QU@#"?!$(98]?B!G:&7.6_K0/)U^^OVZ(D[B)% M^%7=2GF05"JNHOWD33=FEN3YRXR=GN'&M.?*6B6U845>5 RUDOOT7?PY'\ ( MVC,)95I/TOZ-+T/J_A\/UG:O7)3*E>JS^_./HD^V9[+&2$=_]8T 6<,#ZI+F M([/'>&J!7/?!Q&-R15,_ER"?6()LCR:!]PDR?]:.HJ@\YA?+&7P?./P\"Q3] MZ:<3RZR>2M)E+@N&T";>:ZMC,>X8&85<"D85?NKD3 ;42S P+^(!CT]+W[F0 M'UH\V.?Z\O;$7'*R'3YC[\QE0W_W;>K>X!1?X^6KEFN:92[;?&=%Q,C%)\I- M:/LAN0P"%W;:&"KZ3 '3@Z_P"W83;14P%21^C%72$>%]#))Z ^:0#IK!Y#N5 M89RDD8=--Q(V78_^UR#W#4Z@,63VG4I)HD$@_ #*0XR9/I(><_T')!,L1.HA M)]HOI,]=%)-<$HX'6!P@G] GDH_&;D@]YH^E.R&2AESV)ZIEW,#O ?%$[JPX M!4K,(OACZ$<0ZDV2LK[OPN#8#N-W')VCDAQ(QL@WYC$!5E3+@[9CY4&7Y%*W M] A>S![:: Q[.;*<]!MQ ])H['-[9;3Y#1%FF,&""?/>;J8.&_B,_-HBGX826E&,F-(]]X'VFRD3,-H ,@%;R"#KU(R2(?&&$/!4_P-M M[++=TR<_GY)YOXI4?A5#KQX'(9DY)W?IOW[7HXI=O/PB.CQD#XGM4BG7DIKK7G. M#VQ*6+1.Z-MW1^2&"O)7ZHX9^0]#-Y9.H:XI!/9K>5[@\V423*NXG9/@'F+%6C!3'FK38:+XRZ>UCDMR+JB6GNHOK;N-_OGS2+6K+!2@O0,%RM3AG878)9>$>H0!6PS0.3P0_D,X1)] @/%,*HG#^MR+3B9'(1'C M..,6B-GE#R5R@.19/<5\%<,\5=&1I V,!BH]4$>;?1'[%ZR>9JUZL<1"W^AR MF#5/];YT>/P#+6 S>S%BID]G]3SGZGM.M&8D6":#?E-C-J(AM^.(R\S*^4#K MU>H_PT)'P#B9_,B7T@B&P&W,978(W.;YRIDTEDS58H])L@)"Q)6#*;KH#K&N MQG(G./@#AZ&1#%MUPY*TN67JE>K/ITG(0B^; MJR?=F)9>MI[/[S W[40PS??T(K1"-HK6Q=(-2U]Y;Z:NS/A$>)B3S*J=P^SX M)'-=A7,P[U%E&H9*_]LCB;5I'I('W_C> ;TD+9;^G\$;=^#L%!Z@O"[,$[L(A6-MR MC%H<\Q7#D((YX) ;=<;B%C0_E2R^1TRE''HIK2WB!4)MCZW#H6",J/N^P&A0 MIL'E> "8)24S@BY6SM&_76@2J'%$/,Z W^,@#@LI=V&II?1MS)UT(A,"QYA! M_I\2KSOSH(%4&X8$=(I6^I#W>$AJ-=U$HT%9X=$DEB#@WO1NO1OF*N M#S3B@?C &A%1X6TZ4 69Y;Q0*CPG@J<- M5^>8-\BBC>G7C4.V*VVQ;,.F\4!JNF'JZ4^2X!E,C)Y'0C(F8/F,9%Q%#QMZ M=2G9X#V1/ZS5S-\K^#W!-1S<=EM M51D#S(2K3U*'=" )%8RP48\Y3APQX)ZJG?YVM1-_X&2C<:(L9#]Y4&:),]8Z MQO6F;C=QQ! ?/>H(47W5[3IX L>L$B'?XN-]^$&6G]:U]V?WUMDE>3B!; M@PQW8^&EO[H5)86IF,(TW+!"M/,H*YO,&;L38M.Q5#'G:6 VCJI*(! HP& L M#--C0^KV,4D-.U*HCBM@VB@;>]!(]4?'X= 7@"='W^!E-5O'^1X?GQQQQ\$3 M%_.VR;M=P;*R$;E:>OS6P\&KK7NJ-T' M6ML=8+O1)7N%@KT%;.=KDY65]<= QW-?8-0S14TR[_AVS)I>"98_TY$I)7=) MY-,5M@HYD)\?_#B2 M4\BZM'OAB/O"J<&/AKBB+)(K>@_SNO%%Z/F37 WF8B5'08Z"' 4Y"G(4+&Z, M/HRBS-=K?U&PMX#E:[._@.5KLUVO]I!R^.FIT[@-7VL,.>LO?:I0O.+&KP^7 MRK#I+*!WRGA[IVX_[,TQ.0PY##D,.0PY#.O#L.7$X[-BSW#DY,5\V+FAT M;>U;:U/;N!K^?F;.?]"R;:<[DSN7AL!V3@BP94J!!7IV]M..8BN)%MMR)1N: M_?7G>279<4BXM 6ZV]-^*%B2I??ZO!>9[1]VCP?GOY_LL3?G[P[9R?N=PX,! M6ZDWF[^M#IK-W?-=-['6:+79N>:)D9E4"8^:S;VC%;8RR;*TUVQ>75TUKE8; M2H^;YZ?-219':\U(*2,:81:NO/[WO[9IS/X4/*2?FH?ZG5V] L;J.12Z$QH=KG>:#4ZC?46J]=IP5"%4_S\UW;* M3#:-Q,\KF?B8U7DDQTE/R_$DVXJY'LND/E19IN)>*RU',I7:1_N&3$*19+W6 M\ZV12K+ZE:!W>T,5A6[ R+]$K]W!,>-[WV< MR*',V.9FH[W=3%]7N/\L9CTSEA-V)*[8J8IY4N6;WEQY_2(9FG3+G1C*2V:E M_/-*)$;9"H8R/HP$&RH="OWS2FN%0<6127D@DW'YG/(P+)X]S>Z->J"BB*=& M](I?MMB5#+-)#VQVN\^W[!&:_@N+-]W\VF9C:;;A>_U:7G @): M89\D2O]([-OG>=G2P-.;TK[2["".12AY)MBIB 0W@C0VD\VWQ3"@(>-!UJOP M^,3ZO=M[VM>\YPEU\=G$?1?B=R$^*'$S JJT]N'/T1QL>,_^(E XT"(1["R6 MV>2[-KZZ-KKMU?JKMH"0\W.OO[IVRP>GOQ_7!WN$A M.]T[.3X]/V/[!V>#_B$[?W. =W[-N2T;.ZU.&S-'_:/!09_6GKT_/#][T+;NXW.?BS3'A[MG[_JG-;9_R%[\V.VT MVUOL.,C4$!IIK]><5HJ) <', ####DC2"7?]AAH>@P9[>3X1[(B;D']@9YD* M+M@[KB]$QLZF,7CJL0&,X*<>XE\4]8+ASCO4H[O55FD7[,N%) M@,0 U;U3]"-Q=8-^'@FJ;I:EE9/,L'=PWU#8*3:_GTA/Q:5( MO6JL,[ 2 =2![M<-.X\=ZWSJM9]M48+L:M(C!#X'9L)3'8[M>YM1+4W:MW.;41] MLLR?%FYN;4)_$^ASA"SFP*KSH4#C:P3:9:!1WE_\\2:Z6-M:[/OV"*J=+DD@E$X2R[8I8:YA[CR(E9GK7 5F\[""ZR_JK6:K5J#%L^:S7: M+8:T&WY@X UF H>TKA+**"<:[$AM#J,J9%G0Z*[=N-_"3O=GI-5@;#?7Y)OW M8[Q6^C *>$V-_I!UGQ/I6 1"#8\$98C%W-ISARY(''%(C8U%(C0\G 9Y&,L$ MN.C: $Q\3 EGJF^O/I]#@;.[=KD4B[NP*VY8S&4231G/,BV'N;LTHD#0WK!J M(J@J7^3&J$#:H',ELXD53 BF(Y7&L#3BDH:JM0,<)8/XK=QI*(^X9K VS5,I MC,^[/3A"DO[$%&=@O_)@+2)[*@BC T[<-+UU+H))HB(UGK)#A\:L/X:J+#V6 MR-W\0K#W"22@CL$- MC^%/\J\Y75YGJ:1D3JW[7TH&+XW1^LIJQQ%%LL@-1+ZV89_O[Q6U@N 1EYHZ M<;DHU(Y8GL$&2? VK(?"FV\D^5!&)/N15K%=FRK2(*7-@NN$J3RC?:\F,IB M"1WVWH-B23386^AP]F:E2K05&[E504&:ZV!BW<-'UTH!)Q,X)R+Y]-'+J4<* MB@[& ]BZ[OW8LO]NBR_SY' QUBAUP[JG;-_^P[I=?BE#=@+33]2T MQ@83& P"7:&K'<6A&[CPBQ_;&U3\UP=[QS7W &PG5Q!AK>@-_(:H /1&4I5; MEW$Q"J\K[*6K>9+-BY$M%65947\3-L]0BZZ]74=C*)1 R0B1$QIEX R P*:,LLM$U=P$JF#0\LCU/*.Y/XC/+PB[.QF\QP\S$; M6/TAX<2MG:F'YO,::X_JVE^Q*[-/'BQ"U[_J;M;N:/\!F#^Q==:PCMS:V'I' M';-L AQ81\Y&L8?RNH0:9(3PW5=X,T^0BX#?":>L!0^YK1!OH,DYM=\>9$E* M_H:S %&AA!(&^YA)8_)JYZZ!/4M0( 20H*C@A1BHBL2?-4\%X@[@X5I5![P" M0L0NI0$0(NQ.9+HT+VG,#BA)]P=5-K7'8%= JPBKK%$$CTO9;D"N5O-I!$5; M$HWE7J44E(67BM_?[1 JQPL#-93K!5H9I^?WC3-?T2*?I/ ^42:E(@S1-T? M!DD#$7)M?//X#. KV1N_B%[U!QTJP_K($"@1)FIV> I-9'-+WTF8_#)AC'C@ MD@A8W_YN'W ]ILZ!)OA=[O;D:K;\6W3&>_<%'[4BFX$)?9*G"_)3/A;U(;*V MBSH?@<,>CZ[XU&RY[Z?:K9;[^NJ?69FNW-C0?VHZ@E_>G=2;=]PR/#U1YR=_ M,Y+JWGLII8EHSOJN[WW9F(%T"'1:7-'B0RYMU>P6Y%HTV(Z@:L"PH:")?G]G M!_""L@1P2S4* 6=YQ@S1O+]7D9<*5L".KT!LP $X-=A+@K\"KG,J=E#3_K3L M_L:?@P))4$V\WQ^(@TSI;^[JB8:G@4TF5Y4^Z+S-."$MA/ (%A M"=I&9&R(NCIQB6(9*")7G8T3Z!+(18B0"@L+)1UTL-)CGOB:L8*&3%TEIA+L MD+T&46Z(%?MY[6Q.L1,DR7PPS41]L./*0QP&?-"SV&CYXN$EMU=5%;8J+=!B MP[+0;OB1!^ZM_UW:9-]FAK<83V/D0+:P,63E/J=P9;06L40U=4OF1%^A8)D1 M^M(G#?@-#N_B.O;S;:$: S,Y7#G+?6.O:$K1_O-%$Z5\=,,*(K9O*S^;VM\F_FE&[>Z*LHQ+)T8FS(GQ+; MKIU/ E1Y9HKL@OC5*EHF%Y![%W\R0;[K=T)N@-%RH^/_'NS6VYL@!;J*98 B MP#9R[<5;S;<^RDZ(R=,4K <3G.6R8W!).>\UPLI\:1RIH6L7TY_?V8XP4G5[ MM>9V+&[\0Y^RT1?TI M^Y=90^6O]R@;XQH"KW2:S#QGE0XWO7]PPJB+/E*15,NI]$10%B(R:8])E?O; M0VL71?\,#XFZ].SZERKB=,1B;(A2):%!FR5.YG>>J7/Q]J9HJ*ED*9W%OO=2 MY$QO) BKSW )B7DBG;\4)C>4*IUPN&T@TSR)Y):B9"&9I^/46%@ F5W]S"ZQ M"=?GD+!T%,V+:0D=54CU5JK4( E3ZLIC\@B[)=& M[EU%=\6$_?9Y'AYGH0/.2(M*F R%";0-XB,)VTZ@U@HDV4^2W'X5:2_JX+?(L&+6 M;M7?UHKOP &_;MI4YW]U92(H'.2:K@86%G7K;RWU(358%F)KP5\H31!Q&1N[ MEP*BC+WI4I&9#XWXD M;8VJ!)%_89;<$N4KLI[M$%_8"J2%;:O[8VI>ZM>ZK M"&I$%2XQV^3IRX:'O #\K"/^04WX[:;_^_7MIO\[^?\!4$L! A0#% @ MG85/4S$-"B^T! 9A8 !$ ( ! &-C96PM,C R,3$P M,34N>'-D4$L! A0#% @ G85/4TVY>'\N!P ]DL !4 M ( !XP0 &-C96PM,C R,3$P,35?;&%B+GAM;%!+ 0(4 Q0 ( )V%3U.R MH:*4! 4 !HM 5 " 40, !C8V5L+3(P,C$Q,#$U7W!R M92YX;6Q02P$"% ,4 " "=A4]3&MI! 4X1 #ZJ0 % M@ %[$0 8V-E;"TX:U\R,#(Q,3 Q-2YH=&U02P$"% ,4 " "=A4]3)]"? M^3 . "8/P $ @ '[(@ 8V-E;"UE>#DY,5\V+FAT;5!+ 4!08 !0 % $4! !9,0 ! end